Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BMY
BMY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BMY News
Bristol-Myers Squibb Co: Findings Indicate Camzyos Could Be the First Targeted Pharmacological Treatment for OHCM in Adolescents
22h ago
moomoo
Bristol Myers Squibb Reports Positive Results for Heart Drug Camzyos
15h ago
seekingalpha
Camzyos Achieves Positive Results in Adolescent Hypertrophic Cardiomyopathy Trial
21h ago
Newsfilter
Bristol-Myers Squibb Stock Analysis and Outlook
1d ago
Yahoo Finance
Bristol Myers Squibb's Cobenfy Clinical Trial Shows Positive Results
2d ago
Newsfilter
CNBC Investing Club March Meeting Overview
2d ago
CNBC
US Stocks Rise on Easing US-Iran Tensions
4d ago
CNBC
AbbVie and Bristol Myers Squibb's Dividend Performance
6d ago
Fool
Dividend Performance of AbbVie and Bristol Myers Squibb
6d ago
NASDAQ.COM
Abraxane and Anktiva Combination Therapy Advances
6d ago
stocktwits
Investors Eye Risks in Dividend Stocks Amid Uncertainty
6d ago
Fool
Viz HCM Showcases New Evidence at ACC Scientific Session
Mar 23 2026
Newsfilter
insitro Expands ALS Treatment Collaboration with BMS
Mar 23 2026
Newsfilter
INSITRO AND BRISTOL MYERS SQUIBB ENHANCE PARTNERSHIP TO FURTHER DEVELOP THERAPEUTIC PROGRAMS FOR AMYOTROPHIC LATERAL SCLEROSIS
Mar 23 2026
moomoo
Camzyos Shows Potential as First Cardiac Myosin Inhibitor for Adolescents with oHCM
Mar 23 2026
Newsfilter
Bristol Myers Squibb: A Stable Dividend Investment
Mar 21 2026
Fool
Show More News
